7.04
+0.22(+3.23%)
Currency In USD
| Previous Close | 6.82 |
| Open | 6.83 |
| Day High | 7.1 |
| Day Low | 6.63 |
| 52-Week High | 70.75 |
| 52-Week Low | 5.21 |
| Volume | 59,433 |
| Average Volume | 112,688 |
| Market Cap | 35.13M |
| PE | -0.48 |
| EPS | -14.79 |
| Moving Average 50 Days | 7.56 |
| Moving Average 200 Days | 17.06 |
| Change | 0.22 |
If you invested $1000 in Mersana Therapeutics, Inc. (MRSN) since IPO date, it would be worth $502.86 as of September 08, 2025 at a share price of $7.04. Whereas If you bought $1000 worth of Mersana Therapeutics, Inc. (MRSN) shares 5 years ago, it would be worth $405.53 as of September 08, 2025 at a share price of $7.04.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Mersana Therapeutics to Host Second Quarter 2025 Conference Call on August 13, 2025
GlobeNewswire Inc.
Aug 06, 2025 12:00 PM GMT
CAMBRIDGE, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical
Mersana Therapeutics Announces 1-for-25 Reverse Stock Split
GlobeNewswire Inc.
Jul 24, 2025 12:31 PM GMT
CAMBRIDGE, Mass., July 24, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical
Mersana Therapeutics Reports Additional Positive Interim Phase 1 Clinical Data for Emi-Le in Oral Presentation at 2025 ASCO Annual Meeting
GlobeNewswire Inc.
Jun 02, 2025 12:10 PM GMT
31% confirmed ORR (8 responses in 26 evaluable patients) across B7-H4 high tumors at intermediate doses 44% confirmed ORR (7 responses in 16 evaluable patients) in the subset of patients with ≤4 prior lines of therapy CAMBRIDGE, Mass., June 02, 202